BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR 74.55
-2.00 (-2.61%)
At close: Mar 27, 2026
BioNTech SE Revenue
In the year 2025, BioNTech SE had annual revenue of 2.87B EUR with 4.32% growth. BioNTech SE had revenue of 907.40M in the quarter ending December 31, 2025, a decrease of -23.75%.
Revenue
2.87B
Revenue Growth
+4.32%
P/S Ratio
6.22
Revenue / Employee
367.61K
Employees
7,807
Market Cap
17.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.87B | 118.80M | 4.32% |
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.58B |
| Siemens Healthineers AG | 23.30B |
| Fresenius SE & Co. KGaA | 22.87B |
| Merck KGaA | 21.10B |
| Fresenius Medical Care AG | 19.63B |
| Sartorius Aktiengesellschaft | 3.54B |
| Fielmann Group AG | 2.42B |
| Carl Zeiss Meditec AG | 2.20B |
BioNTech SE News
- 5 days ago - BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer - GlobeNewsWire
- 12 days ago - BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity. - Barron's
- 17 days ago - Moderna (MRNA) and BioNTech (BNTX) Shares Rise on Advisory Reversal - GuruFocus
- 17 days ago - Morgan Stanley Lowers Price Target for BioNTech (BNTX) to $125 | BNTX Stock News - GuruFocus
- 17 days ago - Canaccord Genuity Reiterates Buy Rating for BioNTech (BNTX) at $171 PT | BNTX Stock News - GuruFocus
- 17 days ago - BioNTech (BNTX): Citigroup Maintains 'Buy' but Slashes Price Target | BNTX Stock News - GuruFocus
- 18 days ago - BioNTech (BNTX) Reports Q4 Loss of EUR0.33/Share as COVID Vaccine Revenue Plunges; Founders Exit - AlphaStreet
- 18 days ago - TD Cowen Maintains Hold Rating on BNTX, Lowers Price Target | BNTX Stock News - GuruFocus